文献库搜索 | GeneLibs

Saglimbeni(GS),Morris(TJ),Hsia(B),Tauseef(... Cancers (Basel) 2026-02-09

...TP53 (83.5%), NOTCH1 (56.3%), KMT2D (47.0%), CDKN2A (44.4%), TERT (41.4%), ROS1 (34.3%), FAT1 (33.3%), NOTCH2 (31.2%), E...

Anaya Aldrete(KB),Muntaqua(D),Garcia-Peter... Cancers (Basel) 2026-02-11

...TP53, RBL1, OSM, TNF, IL1B, IL6, and IFNG. Comparative analysis at both transcription and translation levels revealed co...

Tinoco(G),Husain(M),Liebner(D),Chen(JL),Sa... Cancers (Basel) 2026-02-16

...TP53 mutations were identified in 4 of 7 next-generation sequencing (NGS)-tested DHCS cases, and PD-L1 positivity was de...

Jeurkar(C),King(L),Baek(D),Wilde(L),Keiffe... Cancers (Basel) 2026-02-18

...TP53-mutated AML. We reviewed published clinical trials, preclinical studies, and ongoing clinical trials evaluating tar...

Cozac-Szoke(AR),Cotoi(OS),Mauer(U),Steines... Cancers (Basel) 2026-02-18

...TP53 (65%), APC (49%), and KRAS (44%). APC was the most frequently mutated gene in both pathogenic (class 5) and likely ...

Suzuki(S),Seino(M),Sato(H),Kawai(M),Ogura(... Pharmaceuticals (Basel) 2026-02-12

...TP53 (73.2%) and PIK3CA (46.0%) were the most prevalent genomic alterations in the MpBC cohort. Exploratory analysis sug...

Alifieris(KE),Dalezis(P),Sagredou(S),Anast... Pharmaceuticals (Basel) 2026-02-17

...TP53 was found. Conclusions: Lactam steroidal antimetabolite hybrids, particularly CS23, act as dual TS/DHFR inhibitors,...

Agbektas(T),Pazarcı(Ö),Tas(A),Huseynzada(A... Pharmaceuticals (Basel) 2026-02-18

...TP53, RAD51, BRCA2, CASP2, MYC, MDM2, CDKN1A, ERCC1, ATR, and PRKDC were quantified through qPCR using the ΔΔCt method. ...

Cui(J),Zhang(R),Zhang(X),Zhang(Z),Li(M),He... Medicine (Baltimore) 2026-02-27

...TP53 protein suggested a potential adverse effect on survival (Log-rank P = .057, HR = 2.5). Significant gender disparit...

Zubair(M),Li(J),Qian(J) Comput Biol Chem 2026-08-00

...TP53/PTEN/EGFR in GBM and SBS1/MMR/POLE for APC/KRAS/PIK3CA in COAD), and a model-derived driver burden stratifies survi...